| Stanley F Glazer, MD | |
|
3455 Main St, Ste 5, Springfield, MA 01107-1147 | |
| (413) 733-9600 | |
| (413) 732-6534 |
| Full Name | Stanley F Glazer |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 52 Years |
| Location | 3455 Main St, Springfield, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679570071 | NPI | - | NPPES |
| GLM08483 | Other | MA | BLUE CROSS BLUE SHIELD |
| 035736 | Other | TUFTS HEALTH PLANS | |
| 070006134 | Other | RAILROAD MEDICARE | |
| 12645 | Other | MA | HEALTH NEW ENGLAND |
| 0304276 | Other | UNITED HEALTH CARE | |
| 4841862202 | Other | CT | CONNECTICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 35736 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baystate Medical Center | Springfield, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New England Dermatology Pc | 9436113677 | 18 |
News Archive
More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.
QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.
Could SARS-CoV-2 become just a seasonal nuisance in the next decade, causing just coughs and sniffles like a common cold, suggests new research? Scientists at the University of Utah, USA, tried to predict the possible future of the novel coronavirus using mathematical models that use learnings from the current pandemic on changes in human immunity over time.
› Verified 9 days ago
| Entity Name | Baystate Medical Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548205909 PECOS PAC ID: 5991602971 Enrollment ID: O20040225000080 |
News Archive
More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.
QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.
Could SARS-CoV-2 become just a seasonal nuisance in the next decade, causing just coughs and sniffles like a common cold, suggests new research? Scientists at the University of Utah, USA, tried to predict the possible future of the novel coronavirus using mathematical models that use learnings from the current pandemic on changes in human immunity over time.
› Verified 9 days ago
| Entity Name | New England Dermatology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356348098 PECOS PAC ID: 9436113677 Enrollment ID: O20041117000172 |
News Archive
More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.
QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.
Could SARS-CoV-2 become just a seasonal nuisance in the next decade, causing just coughs and sniffles like a common cold, suggests new research? Scientists at the University of Utah, USA, tried to predict the possible future of the novel coronavirus using mathematical models that use learnings from the current pandemic on changes in human immunity over time.
› Verified 9 days ago
| Entity Name | The Commonwealth Of Massachusetts |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518114388 PECOS PAC ID: 0648356238 Enrollment ID: O20090406000648 |
News Archive
More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.
QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.
Could SARS-CoV-2 become just a seasonal nuisance in the next decade, causing just coughs and sniffles like a common cold, suggests new research? Scientists at the University of Utah, USA, tried to predict the possible future of the novel coronavirus using mathematical models that use learnings from the current pandemic on changes in human immunity over time.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stanley F Glazer, MD 3455 Main St, Ste 5, Springfield, MA 01107-1147 Ph: (413) 733-9600 | Stanley F Glazer, MD 3455 Main St, Ste 5, Springfield, MA 01107-1147 Ph: (413) 733-9600 |
News Archive
More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.
QRxPharma Limited announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US.
Could SARS-CoV-2 become just a seasonal nuisance in the next decade, causing just coughs and sniffles like a common cold, suggests new research? Scientists at the University of Utah, USA, tried to predict the possible future of the novel coronavirus using mathematical models that use learnings from the current pandemic on changes in human immunity over time.
› Verified 9 days ago
Michael Loosemore, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Nadine P Wenner, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3455 Main St, Ste 5, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Sheila Greenlaw, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Dr. Michael D Horwich, MD, PHD Dermatology Medicare: Medicare Enrolled Practice Location: 3455 Main St Ste 5, New England Dermatology & Laser Center, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
David Wartman, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St, Ste. # 5, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Mark A Blumberg, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3455 Main St, Suite 5, Springfield, MA 01107 Phone: 413-733-9600 Fax: 413-732-6534 | |
Dr. Peter T Demos, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 125 Liberty St, Ste 403, Springfield, MA 01103 Phone: 413-739-6611 |